Phase II trial of sorafenib in metastatic thyroid cancer - Wikidata - wikimedia - TriplyDB

Phase II trial of sorafenib in metastatic thyroid cancer

Phase II trial of sorafenib in metastatic thyroid cancer

http://www.wikidata.org/entity/Q37158278

about

Angiogenesis-inhibitors for metastatic thyroid cancer Selective use of sorafenib in the treatment of thyroid cancer Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications Molecular Targeted Therapies of Aggressive Thyroid Cancer The Evolving Treatment Landscape for Metastatic Differentiated Thyroid Cancer Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib Sorafenib in metastatic thyroid cancer: a systematic review Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions Progress in molecular-based management of differentiated thyroid cancer Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis Spinal metastasis in thyroid cancer Current status and future perspectives in differentiated thyroid cancer Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer BRAF activates and physically interacts with PAK to regulate cell motility RET gene abnormalities and thyroid disease: who should be screened and when 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma.Phase II study of sorafenib in patients with relapsed or refractory lymphoma.Update: the status of clinical trials with kinase inhibitors in thyroid cancer Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Current concepts and future directions in differentiated thyroid cancer.Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib.Alternative medical treatment for radioiodine-refractory thyroid cancers.Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.Lessons from mouse models of thyroid cancer.Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer.Anaplastic thyroid cancer: multimodal treatment results.Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyr Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis Update on thyroid cancer treatment.

P2860

Q24236743-53682F70-5A52-4C0D-85EE-6FEDEBA26648 Q26752891-1A44736B-B795-4705-BB0F-8DF5A103004A Q26764899-623C3B93-56F9-414D-BBDE-D7665117D775 Q26774734-EE2319F5-8E34-4943-AD09-46AA477C18FC Q26795503-B12BBF20-83A8-4A0B-B212-EDFE9C31F6E8 Q26821959-56797C86-F0A2-4D70-9413-D280921B26D8 Q26828884-8E7CAB8B-F04E-438E-B087-BC989783594D Q26862841-101B31AD-ABE7-4667-8EF7-4DC4DBE4459A Q26863326-BE5BABA3-14DF-4C98-B3CA-3CDC98D100DD Q26999887-56684178-2731-4666-9A79-839B98CF1765 Q27003304-0E2E9C1A-389C-46CC-B28F-831D04045CD1 Q27003934-0DD35E61-861A-4CD5-9DE5-9D59E19DE5A9 Q27024484-A90D7185-A84F-4E7C-AC92-8D98CBAFC55E Q27027491-BD218954-4E98-4F44-84BD-D9915E5E57AB Q27851560-7DAC78F9-1ECB-482B-85B4-CF17F953212B Q28248127-93CECF0A-729B-4883-B4F9-9143665F969B Q28709562-E8EE9D9B-EFC8-4B7F-8785-2C6ECCA0848A Q30367068-21D2B9C6-75E9-4A16-82E6-F38C8606EFFD Q30458424-D945C624-4767-4C4F-AEBB-9D1374E20627 Q33397349-9DF7B6CA-6EB6-42A8-8234-E5F8A35E2A82 Q33401136-1BAA87C3-0CEB-469F-AECE-BC125716CF28 Q33570056-A8232917-E74C-4F11-9E7C-B9482B4CBE5E Q33577870-1EBE1786-9CF8-47C8-A022-73BFDC873D2E Q33587809-5B7C92FB-3A7A-4DF9-ACE6-8AC1040F179A Q33590611-8D2D466C-6146-43D6-A7F7-E14EDEFB236A Q33620083-DE038A71-0E05-4757-91EA-4998DB19013E Q33632654-F925A03B-F09D-46C4-B7EA-10E91DF76E2A Q33633424-05480113-A295-4D0D-826A-53A28BC44AEB Q33677589-4A80E09C-3E45-4077-938C-E9B425874DC4 Q33682381-67B58F8D-5996-46B3-BD75-1E034AC3F6DC Q33704599-4615829F-3D6E-4F95-AB97-7230E0C7DA74 Q33728406-5A7F5E64-FC96-475B-BDF5-425E085A8ED5 Q33770769-CD97D1B2-0A4E-4204-92E9-380FF706F211 Q33819911-EFABB2E1-1372-4680-B0A0-FE8858927DF5 Q33828409-8511637F-4A1F-4BE0-BB99-25279CD993BC Q33927272-5C7784FE-8504-4483-B9D7-4F6B9FF8AD23 Q33988335-D4842407-D2A3-4073-86CB-2B0974FF0BD4 Q33990855-40628076-E5BD-4783-826C-85D1A4F75F61 Q34272887-245A8177-B4FA-427E-9ABA-3EEE63D32C81 Q34310219-6E200B17-0A67-4889-B852-297C81DB8465

P2860

Phase II trial of sorafenib in metastatic thyroid cancer

http://www.wikidata.org/entity/Q37158278

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phase II trial of sorafenib in metastatic thyroid cancer

@en

Phase II trial of sorafenib in metastatic thyroid cancer.

@nl

type

label

Phase II trial of sorafenib in metastatic thyroid cancer

@en

Phase II trial of sorafenib in metastatic thyroid cancer.

@nl

prefLabel

Phase II trial of sorafenib in metastatic thyroid cancer

@en

Phase II trial of sorafenib in metastatic thyroid cancer.

@nl

P1433

Q37158278-FA387383-D0E4-4A5E-B119-DBD752BE841A

P1476

Q37158278-44C4437F-08DE-4BB3-9D54-315D25FF2DDA

P2093

Q37158278-27A8AC35-DB4A-4AA7-9E74-B58D8D38D1FF

Q37158278-33960F3C-C358-4CAE-AC98-262027FD36A8

Q37158278-49FFE7A8-0A79-40F8-85CE-1EC396090825

Q37158278-4C5CA792-0336-4CE9-B1D9-7D4E83748966

Q37158278-6193FE45-4793-46F4-8D58-2ED7CD3569CB

Q37158278-734A3FEB-50B8-4223-A012-D2F3506E446F

Q37158278-766E44B5-6CD2-4192-A70F-EAD86BBFBDB1

Q37158278-77BFF25D-178A-4955-B12D-4930A39EFF2B

Q37158278-82410D37-4610-40F8-87A5-B68A638FC0D6

Q37158278-89F67729-0303-40ED-9387-28EB067F93D7

P2860

Q37158278-10CAB872-D79B-4911-8610-61E407B5204C

Q37158278-13728EF7-027A-4EB4-A854-43B8E4A88FE0

Q37158278-236C6B4E-EE4A-48FD-8DBB-F10540E9C7BD

Q37158278-2BE6E7E2-67A3-4FC9-9183-9A4E5263E352

Q37158278-39D46B8C-64B4-4288-A119-414798F27ADD

Q37158278-5143BB0D-3713-484A-A3E7-90344F5C9077

Q37158278-521BE847-E5C5-40DD-9618-B0A5F1BED702

Q37158278-55783BA9-3E2B-4BF4-89FF-A345D2D5CE8C

Q37158278-5AE1AB4E-0158-4394-BECF-88C9B05D593B

Q37158278-5CE51ADF-4D67-4CFD-84D9-21B5857C6B82

P304

Q37158278-09B007D0-DED2-45BA-AE88-82729C5C0537

P31

Q37158278-E0C65807-0AE2-40CD-9258-5EED7CA2FE9E

P356

Q37158278-C5E7F1FA-50AC-446E-AB9A-98FBF20F48BA

P407

Q37158278-884BBDBF-EF4D-4628-824D-333F855F5465

P433

Q37158278-51987985-F056-49F7-B81F-FAEEC8514D03

P478

Q37158278-97C82D96-C179-4C7F-A11C-3AE23DF43F0E

P577

Q37158278-4EA75AA7-8D48-4A42-A522-5C5E4138298B

P5875

Q37158278-80A87C29-B932-4B70-BE2C-4602502D7AF5

P698

Q37158278-147314C2-1CB8-4E10-8553-1D560E160FA6

P921

Q37158278-12875393-AD6F-4CF9-85D6-4316834E1CCD

P932

Q37158278-DF39DB1D-3D7B-4731-A604-ADA42875FA87

P356

JCO.2008.18.2717

P1433

Journal of Clinical Oncology

P1476

Phase II trial of sorafenib in metastatic thyroid cancer

@en

P2093

Daria Arbogast

http://www.w3.org/2001/XMLSchema#string

Jennifer Rittenberry

http://www.w3.org/2001/XMLSchema#string

Jiachao Liang

http://www.w3.org/2001/XMLSchema#string

John J Wright

http://www.w3.org/2001/XMLSchema#string

Lai Wei

http://www.w3.org/2001/XMLSchema#string

Manisha H Shah

http://www.w3.org/2001/XMLSchema#string

Mark King

http://www.w3.org/2001/XMLSchema#string

Matthew D Ringel

http://www.w3.org/2001/XMLSchema#string

Michael Grever

http://www.w3.org/2001/XMLSchema#string

Michael V Knopp

http://www.w3.org/2001/XMLSchema#string

P2860

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

MAP kinases and hypoxia in the control of VEGF expression.

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

Motesanib diphosphate in progressive differentiated thyroid cancer.

The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway.

VEGF and the quest for tumour angiogenesis factors.

Functional magnetic resonance imaging in oncology for diagnosis and therapy monitoring.

P304

1675-1684

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.18.2717

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24171688

http://www.w3.org/2001/XMLSchema#string

P698

19255327

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

2668972

http://www.w3.org/2001/XMLSchema#string